US protection ending in 2031: Cancer
As of the edition of 20 October 2026, 43 drugs have US protection that ends in 2031 in cancer; 30 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
43 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Abemaciclib | Ends 2031 (patent) | Marketed | Eli Lilly | CDK4, CDK6 | 2 |
| Alectinib | Ends 2031 (patent) | Marketed | Roche | ALK, RET | 1 |
| Benralizumab | Ends 2031 (orphan exclusivity) | Marketed | AstraZeneca | IL5RA | 0 |
| Bimatoprost | Ends 2031 (patent) | Marketed | AbbVie | PTGFR | 3 |
| Blinatumomab | Ends 2031 (orphan exclusivity) | Marketed | Amgen | CD19, CD3D, CD3E | 0 |
| Bosutinib | Ends 2031 (exclusivity) | Marketed | Pfizer | ABL1 | 1 |
| Brolucizumab | Ends 2031 (computed from the first US licence) | Marketed | Novartis | VEGFA | 0 |
| Cabotegravir | Ends 2031 (patent) | Marketed | GSK | 0 | |
| Cipepofol | Ends 2031 (exclusivity) | Marketed | Haisco-USA Pharmaceuticals | 0 | |
| Daclatasvir | Ends 2031 (patent) | Marketed | Bristol Myers Squibb | 0 | |
| Delgocitinib | Ends 2031 (patent) | Marketed | LEO Pharma | JAK1, JAK2, JAK3 | 4 |
| Dupilumab | Ends 2031 (orphan exclusivity) | Marketed | Regeneron | IL4R | 1 |
| Durvalumab | Ends 2031 (orphan exclusivity) | Marketed | AstraZeneca | CD274 | 1 |
| Elbasvir | Ends 2031 (patent) | Marketed | Merck & Co. | 0 | |
| Enfortumab vedotin | Ends 2031 (computed from the first US licence) | Marketed | Astellas | NECTIN4, TUBB, TUBB1 | 1 |
| Etelcalcetide | Ends 2031 (patent) | Marketed | Amgen | CASR | 1 |
| Fedratinib | Ends 2031 (patent) | Marketed | Bristol Myers Squibb | FLT3, JAK2 | 2 |
| Fostamatinib | Ends 2031 (patent) | Marketed | Rigel Pharmaceuticals | SYK | 3 |
| Gedatolisib | Ends 2031 (exclusivity) | Marketed | Celcuity | MTOR, PIK3CA, PIK3CB | 5 |
| Iberdomide | Ends 2031 (exclusivity) | Marketed | Bristol Myers Squibb | CRBN, CUL4A, DDB1 | 0 |
| Imetelstat sodium | Ends 2031 (exclusivity) | Marketed | Geron | TERT | 1 |
| Inotuzumab ozogamicin | Ends 2031 (orphan exclusivity) | Marketed | Pfizer | CD22 | 0 |
| Isavuconazonium | Ends 2031 (exclusivity) | Marketed | Astellas | 0 | |
| Letermovir | Ends 2031 (exclusivity) | Marketed | Merck & Co. | 0 | |
| Letrozole | Ends 2031 (patent) | Marketed | Novartis | CYP19A1 | 1 |
| Luspatercept | Ends 2031 (computed from the first US licence) | Marketed | Bristol Myers Squibb | TGFB1, TGFB2, TGFB3 | 3 |
| Lutetium oxodotreotide | Ends 2031 (exclusivity) | Marketed | Advanced Accelerator Applications | SSTR1, SSTR2, SSTR3 | 10 |
| Macitentan | Ends 2031 (exclusivity) | Marketed | Johnson & Johnson | EDNRA, EDNRB | 0 |
| Mavorixafor | Ends 2031 (exclusivity) | Marketed | X4 Pharmaceuticals | CXCR4 | 2 |
| Niraparib | Ends 2031 (patent) | Marketed | GSK | PARP1, PARP2 | 6 |
| Nivolumab | Ends 2031 (orphan exclusivity) | Marketed | Bristol Myers Squibb | PDCD1 | 2 |
| Pembrolizumab | Ends 2031 (orphan exclusivity) | Marketed | Merck & Co. | PDCD1 | 1 |
| Polatuzumab vedotin | Ends 2031 (computed from the first US licence) | Marketed | Roche | CD79B, TUBB, TUBB1 | 1 |
| Pomalidomide | Ends 2031 (patent) | Marketed | Bristol Myers Squibb | CRBN | 0 |
| Ribociclib | Ends 2031 (patent) | Marketed | Novartis | CDK4, CDK6 | 2 |
| Romosozumab | Ends 2031 (computed from the first US licence) | Marketed | Amgen | SOST | 2 |
| Rucaparib | Ends 2031 (patent) | Marketed | pharmaand | PARP1, PARP2, PARP3 | 5 |
| Talazoparib | Ends 2031 (patent) | Marketed | Pfizer | PARP1, PARP2 | 2 |
| Telotristat ethyl | Ends 2031 (patent) | Marketed | TerSera Therapeutics | TPH1, TPH2 | 4 |
| Tovorafenib | Ends 2031 (patent) | Marketed | Servier | ARAF, BRAF, RAF1 | 6 |
| Trastuzumab deruxtecan | Ends 2031 (computed from the first US licence) | Marketed | Daiichi Sankyo | ERBB2, TOP1 | 3 |
| Trifarotene | Ends 2031 (patent) | Marketed | Galderma | RARG | 2 |
| Vortioxetine | Ends 2031 (patent) | Marketed | Takeda | HTR1A, HTR3A, SLC6A4 | 5 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2031 in cancer
In the product30 of these 43 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.